New Truveta study highlights patterns of discontinuation and reinitiation of GLP-1 RA medications
Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in JAMA Network Open, offering critical ...
beckerspayer24d
The first state to cover Ozempic under the ACA
As of Jan. 1, individual ACA plans and small-group plans from employers in the state include coverage for GLP-1s and gastric inhibitory polypeptide drugs, according to the North Dakota Insurance ...
inforum28d
North Dakota becomes 1st state to cover weight loss medication with federally backed health insurance
and gastric inhibitory polypeptide drugs as of Wednesday, Jan. 1. The drugs can be used to prevent diabetes and to treat insulin resistance, metabolic syndrome or morbid obesity, according to a ...